Description
The project includes preclinical studies required to advance SOR-C13, a clinical stage oncology drug, for the prevention and/or treatment of COVID-19 into clinical trials.
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $134,682 at start, $66,978 after amendment #2 (−$67,704).
- #02020-09-15$134,682
- #22021-03-09$66,978-$67,704
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-09-15(start date) | $134,682 | — | The project includes preclinical studies required to advance SOR-C13, a clinical stage oncology drug, for the… |
| #2 amendment | 2021-03-09 | $66,978 | −$67,704 | The project includes preclinical studies required to advance SOR-C13, a clinical stage oncology drug, for the… |
Related records · 10
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 826461147)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2020-2021-Q4-968565 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $15,715 | FY2021 |
| 276-2020-2021-Q2-00117 | Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique · REGI - Business Scale-up and Productivity | $500,000 | FY2021 |
| 276-2020-2021-Q2-00567 | Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique · REGI - Business Scale-up and Productivity | $1,000,000 | FY2021 |
| 172-2020-2021-Q3-960291 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Innovation Assistance Program | $41,835 | FY2021 |
| 172-2020-2021-Q1-950396 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $29,475 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-958701 · retrieved 2026-11-13.